Concurrent tamoxifen-related Müllerian adenofibromas in uterus and ovary.

Haiyan Shi, Xiaoduan Chen, Bingjian Lv, Xiaofei Zhang
International journal of clinical and experimental pathology · 2015 · vol. 8(11) , pp. 15381–5 · PMID:26823898 · W2413289052
article OA: green CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This report describes a 45-year-old woman on tamoxifen therapy who developed concurrent Müllerian adenofibromas in her uterus and ovary alongside endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This paper reports a single 45-year-old woman with long-term tamoxifen therapy for estrogen/progesterone receptor–positive breast cancer who developed concurrent proliferative Müllerian-type lesions resembling Müllerian adenofibromas in the uterine cavity and the right ovary, with serial transvaginal ultrasonography showing progressive thickening/enlargement during drug exposure. The uterine curettings showed endometrial hyperplasia, and post-surgical pathology demonstrated endometrioid adenofibroma–type features in both sites with ER/PR positivity, alongside typical adenomyosis/leiomyoma and foci of endometriosis on the bilateral ovarian surfaces. The authors acknowledge uncertainty about whether the ovarian adenofibroma arose from preexisting endometriosis versus reflecting direct tamoxifen effects. This paper is centrally about adenofibromas associated with tamoxifen, while it explicitly notes coexisting endometriosis in the ovarian surfaces and discusses endometriosis as a possible origin and link to tamoxifen-related proliferative changes, making it directly relevant to endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Tamoxifen is a widely used in anti-oestrogen treatment of breast cancer. Previous reports showed that tamoxifen is associated with proliferative endometrial lesions. We herein reported an unusual case of concurrent hyperplastic lesions in the uterine cavity and right ovary in a 45-year-old woman with tamoxifen therapy. Regular vaginal ultrasonography showed the progressive endometrial thickening and right ovary enlargement during the period of drug use. Both lesions in the uterine cavity and right ovary showed characteristics resembling that of Müllerian adenofibroma. There were also foci of endometriosis in her bilateral ovarian surfaces. We suggest that women taking tamoxifen with a known history of endometriosis should be followed with transvaginal ultrasonography periodically.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenofibroma Antineoplastic Agents, Hormonal Breast Neoplasms Carcinoma, Ductal, Breast Ovarian Neoplasms Selective Estrogen Receptor Modulators Tamoxifen Uterine Neoplasms Adenofibroma Adenofibroma Adenofibroma Adenofibroma Antineoplastic Agents, Hormonal Biopsy Breast Neoplasms Breast Neoplasms Breast Neoplasms Carcinoma, Ductal, Breast Carcinoma, Ductal, Breast Carcinoma, Ductal, Breast

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:13.485820+00:00
License: CC0 · commercial use OK